Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Opioid Drugs: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering.
The growth of the global market is attributed to the factors such as the growing prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and growing approval rate of abuse-deterrent formulations of opioid drugs.
The opioid drug market is a fragmented market with numerous small and large players. Market players are investing in the development of novel therapeutics, which is anticipated to drive the market during the forecast period.
The global opioid drug market is segmented based on the product and region.
The report includes:
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor, and Kappa receptor
- Details of technological advancement for the new opioid formulation to reduce the risk of drug abuse
- A case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
- Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
- Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
- Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
Key Topics Covered
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
- Overview: Opioid Drugs
- Types of Opioids
- Receptor Targets of Opioid Drugs
- Mu Receptor
- Delta Receptor
- Kappa Receptor
- Significant Events Related to Opioid Misuse and Abuse
- Technology Advancements in Opioid Drugs
- Abuse-Deterrent Approaches
- Abuse-Deterrent Technologies
- Novel Drug Delivery Systems
- Therapeutic Applications of Opioid Drugs
- Cancer Pain Management
- Surgical Pain Management
- Opioid Use Disorder
- Prescription Drug Monitoring Programs (PDMPs)
Chapter 4 Market Dynamics
- Market Drivers
- Rising Prevalence of Chronic Pain
- Rise in Palliative Care for Patients Suffering from Pain
- New Opioid Formulation to Reduce the Risk of Abuse
- Increasing Incidence of Road Accidents and Surgical Procedures
- Market Restraints
- Widespread Misuse of Opioids
- Increasing Incidence of Death Related to Opioid Overdose
- Growing Number of Lawsuits against Opioid Manufacturers
Chapter 5 Market Breakdown by Product
- Global Market for Opioid Drugs by Product
- Buprenorphine
- Market Size and Forecast
- Market Analysis
- Fentanyl
- Market Size and Forecast
- Market Analysis
- Hydrocodone
- Market Size and Forecast
- Market Analysis
- Morphine
- Market Size and Forecast
- Market Analysis
- Oxycodone
- Market Size and Forecast
- Market Analysis
- Tramadol
- Market Size and Forecast
- Market Analysis
- Others
- Market Size and Forecast
- Market Analysis
Chapter 6 Market Breakdown by Region
- Global Market for Opioid Drugs by Region
- North America
- United States
- Canada and Mexico
- Europe
- Germany
- U.K.
- France
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
Chapter 7 Regulatory Environment
- Regulations in the U.S.
- New Drug Approvals
- The FDA Modernization Act of 1997
- New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
- Risk Evaluation and Mitigation Strategy (REMS)
- Schedules Under the Controlled Substances Act
- Federal Initiatives to Address Non-medical Use of Prescription Opioids
- FDA's Opioid Policy Work Plan
- CDC Guidelines for Prescribing Opioids for Chronic Pain
Chapter 8 Pipeline Analysis
- Overview of the Drug Development Process
- Pipeline Analysis of Opioid Drugs
Chapter 9 Competitive Landscape
- Current Market Scenario
- Key Strategies Adopted by Market Players
- Influence of Generic Drugs on the Global Opioid Drug Market
- Significant Industry Events and Developments
Chapter 10 Company Profiles
- Acura Pharmaceuticals Inc.
- Allergan PLC
- Apotex Inc.
- Assertio Therapeutics Inc. (Depomed Inc.)
- Biodelivery Sciences International Inc.
- Cipher Pharmaceuticals Inc.
- Collegium Pharmaceutical Inc.
- Daiichi Sankyo Inc.
- Egalet Corp.
- Endo International PLC
- Hikma Pharmaceuticals PLC
- Indivior PLC
- Insys Therapeutics Inc.
- Johnson & Johnson
- Kempharm Inc.
- Lannett Co. Inc.
- Lupin Ltd.
- Mallinckrodt
- Mylan NV
- Orexo AB
- Pernix Therapeutics
- Pfizer Inc.
- Purdue Pharma LP
- Sun Pharmaceutical Industries Ltd. (Sun Pharma)
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/zj84gc/global_market?w=12